EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting pleckstrin-2/Akt signaling reduces proliferation in myeloproliferative neoplasm models

Xu Han, Yang Mei, Rama K Mishra, Honghao Bi, Atul D Jain, Gary E Schiltz, Baobing Zhao, Madina Sukhanova, Pan Wang, Arabela A Grigorescu, Patricia C Weber, John J Piwinski und 7 weitere

Journal of Clinical Investigation · 2023

DOI: 10.1172/jci159638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Xu Han und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Feinberg School of Medicine. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, NHLBI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPNs) are characterized by the activated JAK2/STAT pathway. Pleckstrin-2 (Plek2) is a downstream target of the JAK2/STAT5 pathway and is overexpressed in patients with MPNs. We previously revealed that Plek2 plays critical roles in the pathogenesis of JAK2-mutated MPNs. The nonessential roles of Plek2 under physiologic conditions make it an ideal target for MPN therapy. Here, we identified first-in-class Plek2 inhibitors through an in silico high-throughput screening approach and cell-based assays, followed by the synthesis of analogs. Plek2-specific small-molecule inhibitors showed potent inhibitory effects on cell proliferation. Mechanistically, Plek2 interacts with and enhances the activity of Akt through the recruitment of downstream effector proteins. The Plek2-signaling complex also includes Hsp72, which protects Akt from degradation. These functions were blocked by Plek2 inhibitors via their direct binding to the Plek2 dishevelled, Egl-10 and pleckstrin (DEP) domain. The role of Plek2 in activating Akt signaling was further confirmed in vivo using a hematopoietic-specific Pten-knockout mouse model. We next tested Plek2 inhibitors alone or in combination with an Akt inhibitor in various MPN mouse models, which showed significant therapeutic efficacies similar to that seen with the genetic depletion of Plek2. The Plek2 inhibitor was also effective in reducing proliferation of CD34-positive cells from MPN patients. Our studies reveal a Plek2/Akt complex that drives cell proliferation and can be targeted by a class of antiproliferative compounds for MPN therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersNeoplasmsMiceAnimalsProto-Oncogene Proteins c-aktSignal TransductionCell ProliferationJanus Kinase 2Blood ProteinsPhosphoproteins

Stichwörter der Autor:innen

Bone marrowCancerDrug screensHematologyOncology

Substanzen

Proto-Oncogene Proteins c-aktJanus Kinase 2platelet protein P47Blood ProteinsPhosphoproteins

Autor:innen und Institutionen

  • Department of Pathology, Feinberg School of Medicine.
  • Robert H. Lurie Comprehensive Cancer Center.
  • Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine.
  • Department of Chemistry, and.
  • Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Department of Molecular Biosciences, Weinberg College of Arts & Sciences, Northwestern University, Evanston, Illinois, USA.

Förderung

  • Biotechnology and Biological Sciences Research Council
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NCI NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Leukemia and Lymphoma Society
  • Harrington Discovery Institute

Zitieren

APA

Han, X., Mei, Y., Mishra, R. K., Bi, H., Jain, A. D., Schiltz, G. E., Zhao, B., Sukhanova, M., Wang, P., Grigorescu, A. A., Weber, P. C., Piwinski, J. J., Prado, M. A., Paulo, J. A., Stephens, L., Anderson, K. E., Abrams, C. S., Yang, J., & Ji, P. (2023). Targeting pleckstrin-2/Akt signaling reduces proliferation in myeloproliferative neoplasm models. Journal of Clinical Investigation. https://doi.org/10.1172/jci159638

Vancouver

Han X, Mei Y, Mishra RK, Bi H, Jain AD, Schiltz GE, et al. Targeting pleckstrin-2/Akt signaling reduces proliferation in myeloproliferative neoplasm models. Journal of Clinical Investigation. 2023. doi:10.1172/jci159638

BibTeX
@article{Han2023,
  author = {Han, Xu and Mei, Yang and Mishra, Rama K and Bi, Honghao and Jain, Atul D and Schiltz, Gary E and Zhao, Baobing and Sukhanova, Madina and Wang, Pan and Grigorescu, Arabela A and Weber, Patricia C and Piwinski, John J and Prado, Miguel A and Paulo, Joao A and Stephens, Len and Anderson, Karen E and Abrams, Charles S and Yang, Jing and Ji, Peng},
  title = {Targeting pleckstrin-2/Akt signaling reduces proliferation in myeloproliferative neoplasm models},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1172/jci159638}
}
Kostenlos starten →